Q2 2025 13F Holders as of 6/30/2025
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
85.6M
-
Number of holders
-
116
-
Total 13F shares, excl. options
-
62.3M
-
Shares change
-
+1.25M
-
Total reported value, excl. options
-
$180M
-
Value change
-
+$7.44M
-
Put/Call ratio
-
0.02
-
Number of buys
-
71
-
Number of sells
-
-40
-
Price
-
$2.89
Significant Holders of Larimar Therapeutics, Inc. - Common Stock, par value $0.001 per share (LRMR) as of Q2 2025
141 filings reported holding LRMR - Larimar Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q2 2025.
Larimar Therapeutics, Inc. - Common Stock, par value $0.001 per share (LRMR) has 116 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 62.3M shares
of 85.6M outstanding shares and own 72.78% of the company stock.
Largest 10 shareholders include DEERFIELD MANAGEMENT COMPANY, L.P. (21.2M shares), RA CAPITAL MANAGEMENT, L.P. (6.05M shares), Blue Owl Capital Holdings LP (4.93M shares), Opaleye Management Inc. (4.11M shares), MILLENNIUM MANAGEMENT LLC (3.66M shares), BlackRock, Inc. (3.04M shares), VANGUARD GROUP INC (2.14M shares), Alyeska Investment Group, L.P. (2.08M shares), CITADEL ADVISORS LLC (1.34M shares), and TWO SIGMA ADVISERS, LP (1.15M shares).
This table shows the top 116 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.